Generic versions of biologic drugs could hit the market without human trials and allow the market forces to bring down costs, ...
In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...
In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...
Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...
CRISPR ETFs invest in companies perfecting gene-editing technology, potentially key for future disease treatments. Top CRISPR ETFs include ARK Genomic Revolution, Global X Genomics, and WisdomTree ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback